PMID- 25195094
OWN - NLM
STAT- MEDLINE
DCOM- 20150731
LR  - 20220317
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 92
IP  - 3
DP  - 2014 Dec
TI  - Bispecific antibody platforms for cancer immunotherapy.
PG  - 153-65
LID - S1040-8428(14)00135-8 [pii]
LID - 10.1016/j.critrevonc.2014.08.003 [doi]
AB  - Over the past decades advances in bioengineering and expanded insight in tumor 
      immunology have resulted in the emergence of novel bispecific antibody (bsAb) 
      constructs that are capable of redirecting immune effector cells to the tumor 
      microenvironment. (Pre-) clinical studies of various bsAb constructs have shown 
      impressive results in terms of immune effector cell retargeting, target dependent 
      activation and the induction of anti-tumor responses. This review summarizes 
      recent advances in the field of bsAb-therapy and limitations that were 
      encountered. Furthermore, we will discuss potential future developments that can 
      be expected to take the bsAb approach successfully forward.
CI  - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Lameris, Roeland
AU  - Lameris R
AD  - Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 
      1081 HV Amsterdam, The Netherlands.
FAU - de Bruin, Renee C G
AU  - de Bruin RC
AD  - Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 
      1081 HV Amsterdam, The Netherlands.
FAU - Schneiders, Famke L
AU  - Schneiders FL
AD  - Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 
      1081 HV Amsterdam, The Netherlands.
FAU - van Bergen en Henegouwen, Paul M P
AU  - van Bergen en Henegouwen PM
AD  - Division of Cell Biology, Department of Biology, Faculty of Science, Utrecht 
      University, Padualaan 8, 3584 CH Utrecht, The Netherlands.
FAU - Verheul, Henk M W
AU  - Verheul HM
AD  - Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 
      1081 HV Amsterdam, The Netherlands.
FAU - de Gruijl, Tanja D
AU  - de Gruijl TD
AD  - Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 
      1081 HV Amsterdam, The Netherlands.
FAU - van der Vliet, Hans J
AU  - van der Vliet HJ
AD  - Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 
      1081 HV Amsterdam, The Netherlands. Electronic address: jj.vandervliet@vumc.nl.
LA  - eng
GR  - 14-0343/AICR_/Worldwide Cancer Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140820
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Single-Chain Antibodies)
SB  - IM
MH  - Animals
MH  - Antibodies, Bispecific/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - Immunotherapy
MH  - Lymphocyte Subsets/drug effects/immunology
MH  - Molecular Targeted Therapy
MH  - Neoplasms/immunology/*therapy
MH  - Single-Chain Antibodies/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Anti-cancer therapy
OT  - Bi-specific antibodies
OT  - Dual specific retargeting
OT  - Immune effector cells
EDAT- 2014/09/10 06:00
MHDA- 2015/08/01 06:00
CRDT- 2014/09/08 06:00
PHST- 2014/03/23 00:00 [received]
PHST- 2014/06/11 00:00 [revised]
PHST- 2014/08/08 00:00 [accepted]
PHST- 2014/09/08 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
AID - S1040-8428(14)00135-8 [pii]
AID - 10.1016/j.critrevonc.2014.08.003 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 
      10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20.